查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2082161

免疫沉澱市場：依方法、檢體類型、檢體來源、疾病領域、應用和最終用戶分類－2026-2032年全球市場預測

Immunoprecipitation Market by Technique, Sample Type, Sample Source, Disease Area, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，免疫沉澱市場將成長至 115,303 億美元，複合年成長率為 5.34%。

主要市場統計數據
基準年 2025 8.0058億美元
預計年份：2026年 8.4093億美元
預測年份 2032 11.5303億美元
複合年成長率 (%) 5.34%

免疫沉澱分析法蛋白質分離、抗體檢驗、表觀遺傳學、相互作用組圖譜繪製、生物標記發現和靶向蛋白質組學的核心工作流程。對於試劑和試劑盒生產商而言，市場需求主要來自對抗體、蛋白A/G珠、瓊脂糖和磁珠、緩衝液、分離耗材以及用於共免疫沉澱（co-IP）、染色質免疫沉澱（ChIP）、核醣體免疫沉澱（RIP）和質譜分析免疫沉澱（MS-Ready IP）的最佳化檢測方法的持續採購。

市場擴張的驅動力在於公共和私人領域對分子生物學、腫瘤學、免疫學、神經科學、感染疾病和細胞舉措研究的持續投入。包括美國國立衛生研究院 (NIH) 的津貼項目、歐盟的「地平線歐洲」計畫、日本醫療研究開發機構 (AMED) 支持的生物醫學研究以及中國和印度的國家生物技術計畫在內的研究生態系統，持續擴大著對可重複免疫沉澱試劑、經驗證的抗體和樣本製備流程的需求，從而吸引了更多實驗室採用這些產品。

一項變革性的變化，將改變免疫沉澱試劑的使用方式。

免疫沉澱領域正從手動、低通量的檢測方法轉向標準化、基於磁珠的自動化工作流程。研究人員越來越需要能夠減少手動操作時間、提高回收率、處理少量樣本並與下游製程（如蛋白質印跡、qPCR、定序和LC-MS/MS分析）相容的試劑盒。

人工智慧對免疫沉澱工作流程的累積影響

人工智慧 (AI) 透過加速抗體序列分析、表位預測、結合風險評估和實驗設計，正在改善試劑發現和品管。 AI 驅動的影像分析、實驗室自動化數據和蛋白質組學資訊學也有助於更一致地量化蛋白質印跡、顯微鏡、定序和質譜資料集中的免疫沉澱結果。

關於免疫沉澱試劑的關鍵區域性見解

北美仍然是主要的需求中心，這得益於其集中了許多由美國國立衛生研究院 (NIH) 資助的生物醫學研究機構、生物技術公司、製藥研發中心、大學醫學中心和蛋白質組學核心設施。在美國，高價採購檢驗的抗體、磁珠試劑盒和質譜相容的免疫沉澱耗材是推動需求的主要因素；而在加拿大，加拿大衛生研究院 (CIHR) 支持的研究、加拿大基因組舉措以及強大的轉化科學網路也是推動需求的因素。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

東協的需求主要受大學科研的拓展、生物製造投資、感染疾病研究以及新加坡作為區域生物醫學和臨床研究中心的角色所驅動。在海灣合作理事會（GCC）國家，國家醫療衛生轉型計劃、舉措學計畫以及對研究型醫院的投資，正在催生對高品質抗體、標準化樣本製備試劑盒和品管的免疫沉澱流程的特定需求。

主要國家免疫沉澱試劑需求分析

美國在高通量蛋白質組學、癌症生物學、免疫學、神經科學和藥物研發應用領域處於領先地位，也是高品質免疫沉澱（IP）、染色質免疫沉澱（ChIP）、核醣體免疫沉澱（RIP）和共免疫沉澱（co-IP）試劑盒的首選市場。加拿大則專注於基因組學、免疫學、幹細胞科學和轉化醫學，而墨西哥和巴西則代表拉丁美洲的成長機遇，這得益於其學術實驗室、感染疾病研究、腫瘤學計畫以及不斷擴展的生物製藥開發能力。

針對試劑和試劑盒生產商的具體建議

產業領導企業應優先考慮抗體檢驗的透明度、批次可追溯性以及在免疫沉澱 (IP)、染色質免疫沉澱 (ChIP)、重組免疫沉澱 (RIP)、共免疫沉澱 (co-IP) 和質譜聯用等工作流程中的應用特定性能數據。產品系列應包括低起始量試劑盒、磁珠形式、交聯選項、天然和變性方案、用於蛋白質組學的潔淨洗脫系統以及適用於自動化或半自動化樣品製備的形式。

調查方法

本執行摘要基於同行評審文獻、公共資金來源、監管指南、科學聯盟、供應商技術文件和經認可的生物醫學研究資料庫的二手研究。支持分析的資訊來源包括來自美國國立衛生研究院 (NIH)、歐洲地平線計畫 (Horizo​​​​n Europe)、歐洲醫學研究協會 (AMED)、加拿大衛生研究院 (CIHR)、國家生物技術計畫、抗體驗證文獻以及蛋白質組學、基因組學和轉化研究組織提供的公開資訊。

關於免疫沉澱試劑策略的結論

免疫沉澱試劑供應商所處的環境中，可重複性、工作流程整合以及下游流程的資料品質至關重要。客戶不再僅根據價格和產量來評估試劑盒，而是越來越期望獲得檢驗的抗體、穩定的磁珠、柔軟性的實驗方案、低背景性能以及與蛋白質組學、基因組學和表觀遺傳學平台的兼容性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：免疫沉澱市場：依方法分類

  • 標準免疫沉澱分析法
  • 共免疫沉澱分析法
  • 染色質免疫沉澱分析法
  • RNA免疫沉澱分析法

第8章：免疫沉澱市場：依樣品類型分類

  • 培養細胞樣本
  • 原代細胞樣本
  • 組織樣本
  • 生物體液樣本

第9章：免疫沉澱市場：依樣本來源分類

  • 人類
  • 動物
  • 植物
  • 微生物來源

第10章：免疫沉澱市場：依疾病領域分類

  • 腫瘤學
  • 神經病學
  • 免疫學
  • 感染疾病
  • 代謝性疾病

第11章：免疫沉澱市場：依應用領域分類

  • 表觀遺傳學
  • 轉譯後修飾研究
  • 蛋白質分析

第12章：免疫沉澱市場：依最終用戶分類

  • 學術研究機構
  • 受託研究機構
  • 製藥和生物技術公司

第13章：免疫沉澱市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：免疫沉澱市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 免疫沉澱市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • AAT Bioquest, Inc.
  • Abbkine, Inc.
  • Active Motif, Inc.
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • Cell Signaling Technology, Inc.
  • Creative Biolabs
  • Danaher Corporation
  • Diagenode SA
  • EpiCypher, Inc.
  • EpiGentek Group Inc.
  • FUJIFILM Wako Pure Chemical Corporation
  • GenScript Biotech Corporation
  • Hologic, Inc.
  • Merck KGaA
  • Miltenyi Biotec BV & Co. KG
  • New England Biolabs, Inc.
  • Novus Biologicals, LLC
  • OriGene Technologies, Inc.
  • Promega Corporation
  • QIAGEN NV
  • Rockland Immunochemicals, Inc.
  • Sino Biological, Inc.
  • Takara Bio Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-43676CF42C5B

The Immunoprecipitation Market is projected to grow by USD 1,153.03 million at a CAGR of 5.34% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 800.58 million
Estimated Year [2026] USD 840.93 million
Forecast Year [2032] USD 1,153.03 million
CAGR (%) 5.34%

Immunoprecipitation remains a core workflow for protein isolation, antibody validation, epigenetics, interactome mapping, biomarker discovery, and targeted proteomics. For reagent and kit manufacturers, demand is anchored in recurring purchases of antibodies, protein A/G beads, agarose and magnetic beads, buffers, separation consumables, and optimized assay formats for co-IP, ChIP, RIP, and mass spectrometry-compatible IP.

Adoption is supported by sustained public and private investment in molecular biology, oncology, immunology, neuroscience, infectious disease, and cell therapy research. Research ecosystems, including NIH-funded programs in the United States, Horizon Europe in the European Union, AMED-supported biomedical research in Japan, and national biotechnology initiatives across China and India, continue to expand the installed base of laboratories that require reproducible immunoprecipitation reagents, validated antibodies, and standardized sample preparation workflows.

Transformative Shifts Reshaping Immunoprecipitation Reagents

The immunoprecipitation landscape is shifting from manual, low-throughput assays toward standardized, magnetic bead-based, automation-ready workflows. Researchers increasingly require kits that reduce hands-on time, improve recovery, support low-input samples, and remain compatible with downstream Western blotting, qPCR, sequencing, and LC-MS/MS analysis.

A second structural shift is the move from generic antibody use to evidence-backed antibody performance. Published best-practice guidance from the International Working Group for Antibody Validation emphasizes genetic, orthogonal, independent-antibody, tagged-protein, and immunocapture-mass spectrometry validation approaches. This raises the competitive value of highly characterized antibodies, lot-to-lot consistency, transparent certificates of analysis, and application-specific data for IP, ChIP, RIP, and co-immunoprecipitation workflows.

Cumulative Impact of AI on Immunoprecipitation Workflows

Artificial intelligence is improving reagent discovery and quality control by accelerating antibody sequence analysis, epitope prediction, binding-risk assessment, and experimental design. AI-enabled image analysis, laboratory automation data, and proteomics informatics also help researchers quantify immunoprecipitation outputs more consistently across Western blot, microscopy, sequencing, and mass spectrometry datasets.

For kit manufacturers, the cumulative impact is a stronger requirement for digital evidence and workflow intelligence. Suppliers that connect antibodies and consumables with searchable validation data, protocol optimization tools, and AI-assisted troubleshooting can reduce failed experiments and improve customer retention while supporting FAIR data practices, reproducibility standards, and audit-ready documentation in biomedical research.

Key Regional Insights for Immunoprecipitation Reagents

North America remains a leading demand center because of its concentration of NIH-funded biomedical research, biotechnology companies, pharmaceutical R&D sites, academic medical centers, and proteomics core facilities. The United States drives high-value purchases of validated antibodies, magnetic bead kits, and MS-compatible immunoprecipitation consumables, while Canada benefits from CIHR-supported research, Genome Canada initiatives, and strong translational science networks.

Europe is shaped by Horizon Europe, national research councils, biobank networks, and strict quality expectations across Germany, France, the United Kingdom, Italy, and Spain, where reproducibility, documentation, and downstream assay compatibility influence procurement. Asia-Pacific is expanding through China's biopharmaceutical capacity, Japan's mature life science tools ecosystem, South Korea's precision medicine investments, India's biotechnology programs, and Australia's clinical research infrastructure. Latin America, led by Brazil and Mexico, is developing through academic, public health, oncology, and infectious disease research. The Middle East is building selective demand through genomics strategies, cancer centers, and research hospitals, while Africa's opportunities are linked to university-linked biomedical initiatives, infectious disease surveillance, genomics capacity building, and international research collaborations.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN demand is supported by expanding university research, biomanufacturing investment, infectious disease research, and Singapore's role as a regional biomedical and clinical research hub. In the GCC, national health transformation programs, genomics initiatives, and research hospital investments are creating selective demand for premium antibodies, standardized sample preparation kits, and quality-controlled immunoprecipitation workflows.

The European Union is important for quality-conscious procurement, data integrity, cross-border research collaboration, and alignment with reproducibility standards in funded biomedical programs. BRICS countries combine large disease burdens, growing biotechnology ecosystems, public research investment, and expanding domestic biomanufacturing activity, making them attractive for cost-effective but validated reagent portfolios. G7 markets continue to support advanced proteomics, epigenetics, immuno-oncology, and drug discovery workflows, while NATO countries overlap with major biomedical research funders and emphasize resilient supply chains, secure sourcing, and continuity of critical laboratory consumables.

Key Country Insights for Immunoprecipitation Reagent Demand

The United States leads in high-throughput proteomics, cancer biology, immunology, neuroscience, and drug discovery applications, making it a priority for premium IP, ChIP, RIP, and co-IP kits. Canada emphasizes genomics, immunology, stem cell science, and translational medicine, while Mexico and Brazil represent growing Latin American opportunities through academic laboratories, infectious disease research, oncology programs, and expanding biopharmaceutical capabilities.

In Europe, the United Kingdom, Germany, and France are strong markets for validated antibodies, automation-compatible reagents, and MS-ready immunoprecipitation workflows; Italy and Spain add demand through oncology, neuroscience, molecular diagnostics research, and university hospital networks. Russia maintains scientific capacity in molecular biology and biomedical research, although procurement can be affected by sanctions, payment limitations, and supply chain restrictions.

China and India are scaling biotechnology, vaccine, biosimilar, academic, and translational research capacity, supporting demand for cost-efficient and reliable immunoprecipitation kits. Japan and South Korea emphasize high-quality life science tools, precision medicine, stem cell research, and advanced proteomics, while Australia's clinical trials ecosystem, university research base, and biomedical infrastructure sustain demand for reproducible immunoprecipitation products.

Actionable Recommendations for Reagent and Kit Manufacturers

Industry leaders should prioritize antibody validation transparency, lot traceability, and application-specific performance data for IP, ChIP, RIP, co-IP, and MS-compatible workflows. Product portfolios should include low-input kits, magnetic bead formats, cross-linking options, native and denaturing protocols, clean elution systems for proteomics, and formats suitable for automated or semi-automated sample preparation.

Commercial teams should localize technical support for high-growth countries, build relationships with core facilities, and publish protocol data using common sample types, disease models, and downstream readouts. Manufacturers can also differentiate by offering AI-assisted protocol selection, searchable validation datasets, digital certificates of analysis, sustainable packaging, and reliable regional distribution without compromising assay reproducibility.

Research Methodology for Immunoprecipitation Analysis

This executive summary is grounded in secondary research from peer-reviewed literature, public funding agencies, regulatory guidance, scientific consortia, supplier technical documentation, and recognized biomedical research databases. Sources informing the analysis include NIH, Horizon Europe, AMED, CIHR, national biotechnology programs, antibody validation literature, and publicly available information from proteomics, genomics, and translational research organizations.

The methodology applies triangulation across scientific adoption signals, funding priorities, regional research infrastructure, procurement behavior, and technology readiness. It excludes unverified claims and emphasizes observable drivers such as public R&D investment, established assay use, validated workflow requirements, reproducibility expectations, and documented shifts toward automation, AI-enabled analytics, magnetic bead workflows, and multi-omics compatibility.

Conclusion for Immunoprecipitation Reagent Strategy

Immunoprecipitation reagent suppliers are operating in an environment defined by reproducibility, workflow integration, and downstream data quality. Customers no longer evaluate kits only by price or yield; they increasingly expect validated antibodies, consistent beads, protocol flexibility, low-background performance, and compatibility with proteomics, genomics, and epigenetics platforms.

Manufacturers that combine scientific credibility with automation readiness, AI-supported technical enablement, transparent validation data, and region-specific commercial execution will be best positioned to serve demand across academic, pharmaceutical, biotechnology, and clinical research environments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Immunoprecipitation Market, by Technique

  • 7.1. Standard Immunoprecipitation
  • 7.2. Co-Immunoprecipitation
  • 7.3. Chromatin Immunoprecipitation
  • 7.4. RNA Immunoprecipitation

8. Immunoprecipitation Market, by Sample Type

  • 8.1. Cultured Cell Samples
  • 8.2. Primary Cell Samples
  • 8.3. Tissue Samples
  • 8.4. Biofluid Samples

9. Immunoprecipitation Market, by Sample Source

  • 9.1. Human
  • 9.2. Animal
  • 9.3. Plant
  • 9.4. Microbial

10. Immunoprecipitation Market, by Disease Area

  • 10.1. Oncology
  • 10.2. Neurology
  • 10.3. Immunology
  • 10.4. Infectious Diseases
  • 10.5. Metabolic Disorders

11. Immunoprecipitation Market, by Application

  • 11.1. Epigenetics
  • 11.2. Post Translational Modification Study
  • 11.3. Protein Analysis

12. Immunoprecipitation Market, by End User

  • 12.1. Academic And Research Institutes
  • 12.2. Contract Research Organizations
  • 12.3. Pharmaceutical And Biotechnology Companies

13. Immunoprecipitation Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Immunoprecipitation Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Immunoprecipitation Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AAT Bioquest, Inc.
  • 17.2. Abbkine, Inc.
  • 17.3. Active Motif, Inc.
  • 17.4. Agilent Technologies, Inc.
  • 17.5. Becton, Dickinson and Company
  • 17.6. Bio-Rad Laboratories, Inc.
  • 17.7. Bio-Techne Corporation
  • 17.8. Cell Signaling Technology, Inc.
  • 17.9. Creative Biolabs
  • 17.10. Danaher Corporation
  • 17.11. Diagenode S.A.
  • 17.12. EpiCypher, Inc.
  • 17.13. EpiGentek Group Inc.
  • 17.14. FUJIFILM Wako Pure Chemical Corporation
  • 17.15. GenScript Biotech Corporation
  • 17.16. Hologic, Inc.
  • 17.17. Merck KGaA
  • 17.18. Miltenyi Biotec B.V. & Co. KG
  • 17.19. New England Biolabs, Inc.
  • 17.20. Novus Biologicals, LLC
  • 17.21. OriGene Technologies, Inc.
  • 17.22. Promega Corporation
  • 17.23. QIAGEN N.V.
  • 17.24. Rockland Immunochemicals, Inc.
  • 17.25. Sino Biological, Inc.
  • 17.26. Takara Bio Inc.
  • 17.27. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNOPRECIPITATION MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL IMMUNOPRECIPITATION MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL IMMUNOPRECIPITATION MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL IMMUNOPRECIPITATION MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNOPRECIPITATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL IMMUNOPRECIPITATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL STANDARD IMMUNOPRECIPITATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL STANDARD IMMUNOPRECIPITATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL STANDARD IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CO-IMMUNOPRECIPITATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CO-IMMUNOPRECIPITATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CO-IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHROMATIN IMMUNOPRECIPITATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CHROMATIN IMMUNOPRECIPITATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHROMATIN IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL RNA IMMUNOPRECIPITATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL RNA IMMUNOPRECIPITATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL RNA IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CULTURED CELL SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CULTURED CELL SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CULTURED CELL SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PRIMARY CELL SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PRIMARY CELL SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PRIMARY CELL SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TISSUE SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TISSUE SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TISSUE SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOFLUID SAMPLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOFLUID SAMPLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOFLUID SAMPLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HUMAN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HUMAN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HUMAN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANIMAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANIMAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANIMAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PLANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PLANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MICROBIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MICROBIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MICROBIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL METABOLIC DISORDERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EPIGENETICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EPIGENETICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EPIGENETICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POST TRANSLATIONAL MODIFICATION STUDY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POST TRANSLATIONAL MODIFICATION STUDY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POST TRANSLATIONAL MODIFICATION STUDY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PROTEIN ANALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PROTEIN ANALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PROTEIN ANALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ACADEMIC AND RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. GCC IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 130. GCC IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. GCC IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 133. GCC IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. GCC IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. G7 IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 151. G7 IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. G7 IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 154. G7 IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. G7 IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. NATO IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 158. NATO IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. NATO IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 161. NATO IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. NATO IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. CANADA IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 173. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 175. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 176. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. MEXICO IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 180. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 182. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 183. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 184. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 186. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 187. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 189. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 190. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. GERMANY IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 201. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 203. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 204. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. FRANCE IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 208. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 209. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 210. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 211. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 214. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 215. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 217. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 218. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 220. ITALY IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 221. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 222. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 224. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 225. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 226. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. SPAIN IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 228. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 229. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 231. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 232. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 233. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 234. CHINA IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. CHINA IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 236. CHINA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. CHINA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 238. CHINA IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. INDIA IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 242. INDIA IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 243. INDIA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. INDIA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 245. INDIA IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 246. INDIA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 247. INDIA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. JAPAN IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 249. JAPAN IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 250. JAPAN IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. JAPAN IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 252. JAPAN IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 253. JAPAN IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 254. JAPAN IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. AUSTRALIA IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. AUSTRALIA IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 257. AUSTRALIA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. AUSTRALIA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 259. AUSTRALIA IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 260. AUSTRALIA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. AUSTRALIA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. SOUTH KOREA IMMUNOPRECIPITATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. SOUTH KOREA IMMUNOPRECIPITATION MARKET SIZE, BY TECHNIQUE, 2018-2032 (USD MILLION)
  • TABLE 264. SOUTH KOREA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. SOUTH KOREA IMMUNOPRECIPITATION MARKET SIZE, BY SAMPLE SOURCE, 2018-2032 (USD MILLION)
  • TABLE 266. SOUTH KOREA IMMUNOPRECIPITATION MARKET SIZE, BY DISEASE AREA, 2018-2032 (USD MILLION)
  • TABLE 267. SOUTH KOREA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. SOUTH KOREA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)